• Purity

  >90%, by SDS-PAGE with silver staining

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by the ability of the immobilized protein to support the adhesion of BCE C/D‑1b bovine corneal endothelial cells. The ED    ₅₀ for this effect is 0.6-2.4 μg/mL.

• Source

  Mouse myeloma cell line, NS0-derived Pro29-Ala1262, with a C-terminal 6-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  Pro29

• Predicted Molecular Mass

  138 kDa

• SDS-PAGE

  130-150 kDa, reducing conditions

Background: Caspr2

Contact-associated Protein-like 2 (Caspr2) is a type I transmembrane member of the neurexin family of adhesion molecules (1). Human Caspr2 is the vertebrate homolog to Drosophila Neurexin IV, and the human and mouse Caspr2 orthologs share 94% amino acid sequence identity. Human Caspr2 contains two EGF-like domains, one F5/8 type C domain, one fibrinogen C-terminal domain, and four laminin G-like domains. It is highly expressed in neuronal tissue where it is primarily localized to the juxtaparanodal region of the axonal membrane (1, 2). Caspr2 acts in conjunction with 4.1B and Tag-1 as a scaffold that clusters Kv1 potassium channels at the juxtaparanodal region and is critical for axo-glial contacts (1-6). Caspr2 interacts with carboxypeptidase E in Golgi bodies during intracellular trafficking to the cell membrane (7). Caspr2 is also required for dendrite arborization and the normal development of neural networks (8). Mutations in Caspr2 are associated with predisposition to autism spectrum disorders, epilepsy, attention-deficit hyperactive disorder, and schizophrenia (8-11). The presence of autoantibodies against Caspr2 is associated with encephalitis, epilepsy, dysarthria, and paroxysmal kinesigenic dystonia (12-14). R&D Systems in-house testing indicates that Caspr2 can enhance bovine corneal endothelial cell adhesion.

• References:

1. Poliak, S. et al. (1999) Neuron 24:1037.

2. Poliak, S. et al. (2001) J. Neurosci. 21:7568.

3. Horresh, I. et al. (2010) J. Neurosci. 30:2480.

4. Traka, M. et al. (2003) J. Cell Biol. 162:1161.

5. Denisenko-Nehrbass, N. et al. (2003) Eur. J. Neurosci. 17:411.

6. Poliak, S. et al. (2003) J. Cell Biol. 162:1149.

7. Oiso, S. et al. (2009) J. Neurochem. 109:158.

8. Anderson, G.R. et al. (2012) Proc. Natl. Acad. Sci. USA 109:18120.

9. Penagarikano, O. and D.H. Geschwind (2012) Trends Mol. Med. 18:156.

10. Friedman, J.I. et al. (2008) Mol. Psychiatry 13:261.

11. Elia, J. et al. (2010) Mol. Psychiatry 15:637.

12. Lancaster, E. et al. (2011) Ann. Neurol. 69:303.

13. Balint, B. et al. (2013) J. Neurol. Sci. 327:73.

14. Krogias, C. et al. (2013) JAMA Neurol. 70:1056.

• Long Name:

  Contactin Associated Protein-like 2

• Entrez Gene IDs:

  26047 (Human); 66797 (Mouse)

• Alternate Names:

  AUTS15; Caspr2; CASPR2DKFZp781D1846; CDFE; Cell recognition molecule Caspr2; CNTNAP2; contactin associated protein-like 2; contactin-associated protein 2; contactin-associated protein-like 2; homolog of Drosophila neurexin IV; KIAA0868; NRXN4; NRXN4Caspr2; PTHSL1